Morgens Waterfall Vintiadis & Co’s CRISPR Therapeutics CRSP Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,000	Closed	-$609K	–	37
2019 Q4	$609K	Hold	10,000	–	–	0.41%	41
2019 Q3	$410K	Hold	10,000	–	–	0.31%	48
2019 Q2	$471K	Hold	10,000	–	–	0.32%	47
2019 Q1	$357K	Hold	10,000	–	–	0.26%	55
2018 Q4	$286K	Hold	10,000	–	–	0.25%	58
2018 Q3	$444K	Hold	10,000	–	–	0.29%	55
2018 Q2	$588K	Hold	10,000	–	–	0.42%	42
2018 Q1	$457K	Sell	10,000 -20,000	-67%	-$825K	0.35%	51
2017 Q4	$704K	Buy	+30,000	New	+$570K	0.55%	34

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's CRSP Position: Q1 2020 in Review

Morgens Waterfall Vintiadis & Co sold out of CRISPR Therapeutics (CRSP) in Q1 2020, closing a stake of 10,000 shares — an estimated $609K sold.

Morgens Waterfall Vintiadis & Co first reported a position in CRSP in Q4 2017 and held it in 9 quarters. The position peaked at $704K in Q4 2017. 257 funds tracked by Wall St. Rank hold CRSP as of Q1 2020.

Morgens Waterfall Vintiadis & Co reported no remaining CRISPR Therapeutics position as of Q1 2020 after selling out during the quarter.
Morgens Waterfall Vintiadis & Co sold 10,000 CRISPR Therapeutics shares in Q1 2020, an estimated $609K.
Morgens Waterfall Vintiadis & Co first reported a position in CRISPR Therapeutics in Q4 2017 and held it in 9 quarters.
Morgens Waterfall Vintiadis & Co's CRISPR Therapeutics position peaked at $704K in Q4 2017.
257 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2020.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q1 2020, filed 15 May 2020.